Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2021-08-05 00:00:00 ET · period of report 2021-08-03 · accession 0001209191-21-049940 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-05 | 2021-08-03 | PCRX | SLONIN JONATHAN | Chief Clinical Off | A - Grant | $0.00 | +5,000 | 26.4K | +23% | $0 |
| D | 2021-08-05 | 2021-08-03 | PCRX | SLONIN JONATHAN | Chief Clinical Off | A - Grant | $0.00 | +10.0K | 10.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-03 | A | A | 5,000 | $0.00 | 26,350 | D | — | — | (F1) Represents restricted stock units that vest in four equal annual installments beginning on August 1, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-08-03 | A | A | 10,000 | $0.00 | 10,000 | D | $60.79 · — to 2031-07-20 | 10,000 Common Stock | (F2) The stock option vests and becomes exercisable as to 25% of the option shares on July 20, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |